Orphalan becomes the first European company to enter in China's Wilson Disease market

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ORPHALAN-Partnership

More Like This

PR Newswire associated0

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

Oranda Therapeutics Announces Series A Funding Round to support its mission: to improve the lives of patients living with rare disease

Kexing Biopharm made its appearance at CPHI Milan 2024: Launch Ceremony for Apexelsin® in EU market Successfully done

PR Newswire associated0

Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

PR Newswire associated0

Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE

Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer

NICE Enables Access to First Treatment That Targets the Underlying Pathophysiology of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1